en · de · es · fr · pt
aod-9604-notes.peptides4800.com › Topic › Background And Molecular Identity — Worked Examples

Background And Molecular Identity — Worked Examples

By Editorial Desk · published 2026-02-16 · last reviewed 2026-03-27 · Topic

obesity research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-03-27 and is reviewed periodically as new material appears.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideBased on the C-terminal region of human growth hormone.
Amino acid length16 residuesOften described as hGH fragment 176-191.
AppearanceLyophilized powderTypically white to off-white; exact appearance depends on grade.
SolubilitySoluble in waterAqueous solubility depends on pH, ionic strength, and preparation.
Typical storage-20 °C or lowerLyophilized peptide is usually kept cold and dry; solutions may require freezing.

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Related pages on this site

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Supporting material

== Early life and education == Wittliff was born on June 15, 1938 in Taft, Texas, of primarily Eastern European heritage. He is a 6th generation Texan and direct descendant of John Cryer (Crier), who was recruited to settle Texas as part of Stephen F. Austin's original 300 families. He, his brother Bill and their mother Laura moved to Blanco when they were boys. In 1956, Wittliff graduated from San Marcos Academy, a college preparatory school that emphasized military discipline and training at the time. After 2 years of studying Chemical Engineering at Texas Tech University where he was a writer for The Daily Toreador and the National Publication Headquarters for the Arnold Air Society, he received a bachelor's degree in chemistry from University of Texas at Austin. While at UT, Wittliff worked at Clyde Campbell University Shop and modeled to support his education. Wittliff then earned an M. S. Degree in Biochemistry at Louisiana State University, School of Medicine. Wittliff's family moved to the University of Texas at Austin where he was awarded an National Defense Education Act (NDEA) Fellowship, a program influenced by the launch of the Sputnik satellite by the Soviets. Wittliff received his Ph.D. degree at The University of Texas at Austin in 1967. He then received an NIH Postdoctoral Award to study in the Laboratory of Professor Francis T. Kenney in the Biology Division at Oak Ridge National Laboratory.

=== Naming of the isotope and Nobel Prize === Urey created the names protium, deuterium, and tritium in an article published in 1934. The name is based in part on advice from Gilbert N. Lewis who had proposed the name "deutium". The name comes from Greek deuteros 'second', and the nucleus was to be called a "deuteron" or "deuton". Isotopes and new elements were traditionally given the name that their discoverer decided. Some British scientists, such as Ernest Rutherford, wanted to call the isotope "diplogen", from Greek diploos 'double', and the nucleus to be called "diplon". The amount inferred for normal abundance of deuterium was so small (only about 1 atom in 6400 hydrogen atoms in seawater [156 parts per million]) that it had not noticeably affected previous measurements of (average) hydrogen atomic mass. This explained why it hadn't been suspected before. Urey was able to concentrate water to show partial enrichment of deuterium. Lewis, Urey's graduate advisor at Berkeley, had prepared and characterized the first samples of pure heavy water in 1933. The discovery of deuterium, coming before the discovery of the neutron in 1932, was an experimental shock to theory; but when the neutron was reported, making deuterium's existence more explicable, Urey was awarded the Nobel Prize in Chemistry only three years after the isotope's isolation. Lewis was deeply disappointed by the Nobel Committee's decision in 1934 and several high-ranking administrators at Berkeley believed this disappointment played a central role in his suicide a decade later.

== See also == Dimethoxyamphetamine Substituted methoxyphenethylamine DOx (psychedelics) Stimulant § Serotonin 5-HT2A receptor agonists Motivation-enhancing drug § Serotonin 5-HT2A receptor agonists 2,5-Dimethoxyphenethylamine (2C-H) 2,4,5-Trimethoxyamphetamine (2,4,5-TMA, TMA-2, or DOMeO) 5-HT2A receptor § Anti-inflammatory effects

Sources: en.wikipedia.org

Supporting material

=== Notch signaling === In 2015 and 2017, Garcia published articles in Science describing the first atomic-level visualizations of Notch signaling complexes. Garcia's group used directed evolution to strengthen low-affinity interactions between the receptor Notch1 and ligands Delta-like 4 (DLL4) and Jagged1 (Jag1) as a means of stabilizing the complexes for co-crystallization. Notch1-DLL4 and Notch1-Jag1 structures were determined by x-ray crystallography and revealed long, narrow binding interfaces assisted by multiple O-linked fucose and glucose modifications on Notch1. O-linked glycans are rarely observed at protein-protein interfaces, and their presence at the Notch-ligand interface explained how changes in glycosylation state influence Notch signaling activity. Garcia's 2017 publication also established that Notch-ligand interactions form catch bonds, and that Delta-like and Jagged ligands have different mechanical force thresholds for Notch receptor activation.

==== Neural ==== Oxytocin secretion in response to suckling or vagino-cervical stimulation is mediated by some of these pathways; vasopressin secretion in response to cardiovascular stimuli arising from chemoreceptors in the carotid body and aortic arch, and from low-pressure atrial volume receptors, is mediated by others. In the rat, stimulation of the vagina also causes prolactin secretion, and this results in pseudo-pregnancy following an infertile mating. In the rabbit, coitus elicits reflex ovulation. In the sheep, cervical stimulation in the presence of high levels of estrogen can induce maternal behavior in a virgin ewe. These effects are all mediated by the hypothalamus, and the information is carried mainly by spinal pathways that relay in the brainstem. Stimulation of the nipples stimulates release of oxytocin and prolactin and suppresses the release of LH and FSH. Cardiovascular stimuli are carried by the vagus nerve. The vagus also conveys a variety of visceral information, including for instance signals arising from gastric distension or emptying, to suppress or promote feeding, by signalling the release of leptin or gastrin, respectively. Again, this information reaches the hypothalamus via relays in the brainstem. In addition, hypothalamic function is responsive to—and regulated by—levels of all three classical monoamine neurotransmitters, noradrenaline, dopamine, and serotonin (5-hydroxytryptamine), in those tracts from which it receives innervation.

=== Byzantine mosaics === Raymond created 55 plates grouped together under the title Essai de reconstitution de mosaïques byzantines (Attempt to reproduce Byzantine mosaics). He portrayed the most famous mosaics of Greek, Italian and Turkish churches. He used photographs that he divided into segments and then scale reproduced down to the finest detail; a technique that would much later be known as “micro-mosaics”.

Sources: en.wikipedia.org

Supporting material

Spironolactone is rapidly and extensively metabolized in the liver upon oral administration and has a very short terminal half-life of 1.4 hours. The major metabolites of spironolactone are 7α-thiomethylspironolactone (7α-TMS), 6β-hydroxy-7α-thiomethylspironolactone (6β-OH-7α-TMS), and canrenone (7α-desthioacetyl-δ6-spironolactone). These metabolites have much longer elimination half-lives than spironolactone of 13.8 hours, 15.0 hours, and 16.5 hours, respectively, and are responsible for the therapeutic effects of the medication. As such, spironolactone is a prodrug. The 7α-thiomethylated metabolites of spironolactone were not known for many years and it was originally thought that canrenone was the major active metabolite of the medication, but subsequent research identified 7α-TMS as the major metabolite. Other known but more minor metabolites of spironolactone include 7α-thiospironolactone (7α-TS), which is an important intermediate to the major metabolites of spironolactone, as well as the 7α-methyl ethyl ester of spironolactone and the 6β-hydroxy-7α-methyl ethyl ester of spironolactone. Spironolactone is hydrolyzed or deacetylated at the thioester of the C7α position into 7α-TS by carboxylesterases. Following formation of 7α-TS, it is S-oxygenated by flavin-containing monooxygenases to form an electrophilic sulfenic acid metabolite. This metabolite is involved in the CYP450 inhibition of spironolactone, and also binds covalently to other proteins. 7α-TS is also S-methylated into 7α-TMS, a transformation catalyzed by thiol S-methyltransferase.

=== 28 May === The Mayor of Kyiv, Vitali Klitschko, claimed that Russian drones attacked the Ukrainian capital. Two people were killed by falling drone debris, while a woman was injured. Two high-rise apartments were set on fire. The Ukrainian Air Force claimed that 58 out of 59 drones had been shot down, with more than 40 of them intercepted over Kyiv. Fires were reported in the Solomyanskyi, Holosiivskyi and Pecherskyi Districts. The attack came on the anniversary of Kyiv's founding in 482 AD. It was later described as Russia's largest drone attack on Kyiv since the war began. Air raid alerts were activated in 12 oblasts, from Volyn in the north-west to Dnipropetrovsk in the south-east. There were also reports of explosions in Zhytomyr, where at least 26 residential buildings were damaged as well as schools and medical units. Shelling was also reported in Sumy Oblast, which borders Russia, and in Nikopol, across the Dnipro River from the Zaporizhzhia Nuclear Power Plant. Russia said its air defences shot down several drones approaching the Ilsky oil refinery in Krasnodar Krai. The Ukrainian General Staff claimed that 80 Russian soldiers deserted their positions in Lysychansk, Luhansk Oblast, while 30 others deserted from Bakhmut. Valerii Zaluzhnyi, Commander-in-Chief of the Armed Forces of Ukraine, reported that all the preparations for the anticipated major counter-attack are complete and that they were only waiting for the decision to strike.

=== Diabetes and obesity === Lacking anti-inflammatory dermal macrophages in diabetic patients results in impaired wound healing ability. Dermal macrophages are arrested at the pro-inflammatory phenotype, which increases the difficulty in the healing process due to their production of pro-inflammatory cytokines. Ulcers on foot are common in a patient with severe diabetes due to the prolonged impairment of wound healing. Pro-inflammatory (M1) macrophages are also frequently observed in obese individuals' subcutaneous tissues. This is related to the progression of diabetes with chronic adipose tissue inflammation. However, the explicit roles of dermal macrophages in obesity are still unclear.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Is AOD-9604 the same as human growth hormone?

No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.

Does AOD-9604 occur naturally?

The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Network